Alfa-sinucleina
Safety and immunogenicity of the α-synuclein active immunotherapeutic PD01A in patients with Parkinson’s disease: a randomised, single-blinded, phase 1 trial
The Lancet Neurology Fecha de publicación: July 2020 DOI: https://doi.org/10.1016/S1474-4422(20)30136-8 Autores: Dieter Volc, MD., Prof Werner Poewe, MD., Alexandra Kutzelnigg,...
